Welcome to our dedicated page for Cartesian Therapeutics SEC filings (Ticker: RNAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cartesian Therapeutics, Inc. filings document the regulatory disclosures of a late clinical-stage biotechnology company developing cell therapy candidates for autoimmune diseases. Recent Form 8-K reports furnish quarterly and annual financial results, business updates, corporate slide presentations, and clinical disclosures for Descartes-08, including autoimmune indications such as generalized myasthenia gravis, myositis, juvenile dermatomyositis and systemic lupus erythematosus.
Proxy materials cover director elections, board committee service, executive compensation, equity awards and other governance matters. Additional 8-K filings report board changes and compensatory arrangements, while the company's disclosures also describe cash resources, FDA designations, forward-looking statements and equity incentive activity tied to its common stock.
Barclays PLC reports a significant ownership position in Cartesian Therapeutics Inc. (common stock). Barclays discloses that it beneficially owns 1,760,326 shares of Cartesian’s common stock, representing 5.99% of the class as of June 30, 2026.
Within this total, Barclays has sole voting powershared voting powersole dispositive powershared dispositive power
Cartesian Therapeutics, Inc. is a late clinical‑stage cell therapy company focused on autoimmune diseases, led by its autologous CAR‑T candidate Descartes‑08 for generalized myasthenia gravis and myositis. Descartes‑08 has Orphan Drug, Regenerative Medicine Advanced Therapy and Rare Pediatric Disease designations from the FDA.
For the three months ended June 30, 2026, revenue was $0, operating expenses were $29.2 million, and net income was $15,769 (amounts in thousands), driven mainly by a $49,200 non‑cash gain from remeasuring the contingent value rights liability, partially offset by a $4,535 loss on an embedded derivative and $852 of interest expense. For the six‑month period, the company recorded $78 of grant revenue, $55,732 of operating expenses and a net loss of $23,413 (all in thousands), with operating cash outflows of $43,217 thousand.
As of June 30, 2026, cash, cash equivalents and restricted cash totaled $149.3 million, and management believes this will fund planned operations for at least the next 12 months. Liquidity is supported by a new senior secured Term Loan Facility with commitments up to $150.0 million (of which $50.0 million is drawn, including a convertible component) and an at‑the‑market equity program that raised $19.3 million in the first half of 2026.
Cartesian Therapeutics, Inc. reported results for the quarter ended June 30, 2026, while advancing multiple clinical programs for its lead CAR-T candidate Descartes-08 in autoimmune diseases. The Phase 3 AURORA trial in generalized myasthenia gravis is enrolling about 100 patients, with top-line data expected in 1Q27 and a planned BLA filing in mid-2027.
The company is also running the Phase 2 TRITON trial in myositis, with subset data expected in 1H27 to guide a potential pivotal trial, and the Phase 1/2 HELIOS pediatric trial in juvenile dermatomyositis and other autoimmune diseases, with data expected in 1H27. A new strategic licensing agreement with WestGene supports an in vivo CAR-T platform; a Phase 1 MG trial using targeted lipid nanoparticles is expected to start in 2H26, with in-human data in 1H27.
Liquidity is supported by approximately $149.3 million in cash, cash equivalents and restricted cash as of June 30, 2026 and a credit facility with K2 HealthVentures providing up to $150 million in non-dilutive financing, including an initial $50 million term loan funded in May 2026. The company expects these resources to fund planned operations into 2028. For the quarter, net income was $15.8 million, or $0.47 basic net income per share, with research and development expenses of $20.4 million and general and administrative expenses of $8.7 million.
JPMorgan Chase & Co. filed an amended Schedule 13G reporting its beneficial ownership in Cartesian Therapeutics, Inc. (common stock). The firm reports beneficial ownership of 1,486,252 shares of common stock, representing 4.8% of the class as of June 30, 2026. JPMorgan Chase & Co. has sole voting power over 1,397,213 shares and sole dispositive power over 1,486,252 shares, with no shared voting or dispositive power. The filing notes that this represents ownership of 5 percent or less of the class, and identifies JPMorgan Chase Bank, National Association, and J.P. Morgan Investment Management Inc. as relevant subsidiaries.
Cartesian Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. A total of 24,151,536 common shares were represented, equal to approximately 82.42% of shares outstanding as of the April 14, 2026 record date, indicating strong turnout.
Stockholders elected three Class I directors to serve until the 2029 Annual Meeting. They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, and ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting proposed and recent transactions in Common stock of RNAC. The filing lists planned exercises and restricted-stock vesting dated 06/09/2026 and 01/02/2026
The filing also reports a disposition by Milos Miljkovic of 3,924 shares on 06/02/2026 for $25,152.84. The itemized entries show multiple issuances/exercises under registered plans with share counts explicitly listed.
Cartesian Therapeutics entered a strategic licensing agreement with WestGene Biopharma to develop novel in vivo CAR-T therapies for autoimmune diseases. The collaboration combines Cartesian’s mRNA payload from Descartes-08 with WestGene’s targeted lipid nanoparticle platform.
WestGene’s in vivo mRNA CAR-T platform has early clinical data showing favorable safety, including repeated dosing of up to 14 infusions in a single patient with only one Grade 1 cytokine release syndrome event reported. The partners plan a Phase 1 dose-escalation study in generalized myasthenia gravis using mRNA from Descartes-08 delivered via WestGene’s nanoparticles, with trial initiation expected in the second half of 2026 and first clinical data expected in the first half of 2027.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice concerning proposed sales of Common stock tied to restricted stock vesting under a registered plan. The excerpt lists proposed sale entries with dates 01/02/2025 and 01/02/2026, and a filing-related date of 06/02/2026.
The notice identifies amounts and line items such as 3924, 1,235, and 2,689 associated with the vesting entries; the filing shows the broker name and NASDAQ as the market. Timing and cash‑flow treatment for any transactions are not specified in the provided excerpt.
Cartesian Therapeutics entered a senior secured Loan and Security Agreement providing up to $150.0 million in term loans from K2 HealthVentures, with an initial $50.0 million tranche funded and additional tranches tied to clinical, approval and sales milestones or lender discretion.
The debt matures on June 1, 2030, bears interest at the greater of 8.95% or the prime rate plus 2.20%, and includes minimum cash and future revenue covenants as the company advances Descartes-08 through late-stage trials.
Lenders may convert up to $15.0 million of principal into common stock at $8.2526 per share or qualifying financing prices, subject to ownership caps. The company expects the initial funding to extend its cash runway into 2028 while it targets key data readouts and a planned BLA filing in 2027. Chief Medical Officer Milos Miljkovic, M.D., is resigning effective May 31, 2026, with severance consistent with his employment agreement.
CARTESIAN THERAPEUTICS INC ownership update: institutional investor FMR LLC reports beneficial ownership of 799,743 shares of Common Stock, representing 3.0% of the class as of 03/31/2026. The filing also lists Abigail P. Johnson with dispositive power over the same 799,743 shares.
The filing is an Amendment No. 4 to a Schedule 13G/A and includes a reference to a 13d-1(k) agreement in Exhibit 99 and a power of attorney incorporated by reference.